AIM Pharmaceutical International Limited

AIM Pharmaceutical International Limited, founded in Dec, 2023
A PolyU academic-led start-up
Incu-Bio program of HKSTP
TSSSU program of ITC

AIM Pharmaceutical International Limited (AIM Pharma) is a pharmaceutical start-up registered in Hong Kong SAR in December 2023. AIM Pharma specializes in research and development of novel therapeutic drugs for the treatment of neurodegenerative disorders. We adapt a unique approach for drug discovery and development process. Such technology speeds up the drug screening process during the early stage of drug discovery and increase the successful rate of the subsequent drug development process. It is a patented invention originated from a decade of cutting-edge pharmaceutical research from our founders.

Our core technology platform, LifeChip Technology is a patented invention that combines our unique zebrafish & organoid disease models and automated high content drug screening system together with well-defined drug discovery strategies. LifeChip Technology accelerates the drug development process by efficiently identifying safe and effective lead compounds and advancing potential therapeutics into the drug pipeline. Our research and development currently focus at addressing diseases related to aging populations, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Multiple Sclerosis (MS).

Leveraging our core technology, we have identified three drug candidates that target neurodegenerative diseases. Our first drug candidate, AIM-01-PD, is a natural, plant-based medicine for the treatment of PD and its novel mechanism of action includes activation of immunoproteasome. We have strong Proof-of-Principle evidence of protective and rescue effect on neurodegenerations and associated symptoms in animal studies. We have enormous experimental data of neuroprotective effects on neurons in the brain; and improved behavioral and cognitive impairments in multiple PD mouse models. Pharmacokinetic and toxicity results have proved that AIM-01-PD has high level of safety, it has fast absorption, high bioavailability, and the ability to cross the blood-brain barrier. A total of six global patents granted (US, EU, Spain, China and Japan) covering treatment claim of new chemical entity, synthesis method, therapeutic use and application. We are moving into the final preparation of pre-clinical studies, toward IND (Investigational New Drug) application.

In January 2024, we have been entered the TSSSU-O program of ITC HKSAR (receiving up to 1M HKD) and in March 2024 we have received top up investment offered by PolyU Entrepreneurship Investment Fund (Angel fund up to 500,000 HKD). In October 2024, we have officially entered the Incu-Bio program, HKSTP. We have an aggressive but realistic development plan. At the end of 2026, we aim to complete pre-clinical studies and GMP production of AIM-01-PD for the phase І clinical trial and submit IND application for our first drug candidate (AIM-01-PD).